Compare Johnson & Johnson (JNJ) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kimberly Clark Corp — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Kimberly Clark Corp trades at $108.46 (market cap $36.11B). The key difference: Johnson & Johnson is far larger — about 17.3× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| JNJ | KMB | |
|---|---|---|
Market Cap | $626.09B | $36.11B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $134.81 |
52-Week Low | $172.78 | $93.05 |
Enterprise Value | $654.37B | $41.67B |
Dividend Yield | 2.06% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Kimberly-Clark (KMB) trades at $108.95, up 0.86% on the day, with a neutral technical signal. The stock shows strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, and the company cut its 2026 outlook due to challenges in China and softer consumer demand, as reported by Reuters on August 4, 2026.
The outlook is mixed; KMB offers a solid dividend yield and trades below the consensus price target of $113.20, but near-term headwinds from China and volatile shipments pose risks. Analyst sentiment is cautious with 61.29% hold ratings, reflecting balanced optimism for long-term value against short-term operational pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
